439 related articles for article (PubMed ID: 26939747)
1. Biologic therapy in familial Mediterranean fever.
Koga T; Migita K; Kawakami A
Mod Rheumatol; 2016 Sep; 26(5):637-41. PubMed ID: 26939747
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
Koga T; Sato S; Miyamoto J; Hagimori N; Kawazoe Y; Arinaga K; Fukushima C; Yamamoto H; Kawakami A
Trials; 2018 Dec; 19(1):715. PubMed ID: 30594222
[TBL] [Abstract][Full Text] [Related]
3. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
[TBL] [Abstract][Full Text] [Related]
4. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.
Hentgen V; Vinit C; Fayand A; Georgin-Lavialle S
Front Immunol; 2020; 11():971. PubMed ID: 32670263
[No Abstract] [Full Text] [Related]
5. Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).
El Hasbani G; Jawad A; Uthman I
Orphanet J Rare Dis; 2019 Oct; 14(1):224. PubMed ID: 31615541
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever.
Ugurlu S; Hacioglu A; Adibnia Y; Hamuryudan V; Ozdogan H
Orphanet J Rare Dis; 2017 May; 12(1):105. PubMed ID: 28558744
[TBL] [Abstract][Full Text] [Related]
7. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF.
Erten S; Erten SF; Altunoglu A
Rheumatol Int; 2012 Apr; 32(4):1095-7. PubMed ID: 21431291
[TBL] [Abstract][Full Text] [Related]
9. Familial mediterranean fever: a fascinating model of inherited autoinflammatory disorder.
Portincasa P; Scaccianoce G; Palasciano G
Eur J Clin Invest; 2013 Dec; 43(12):1314-27. PubMed ID: 24117178
[TBL] [Abstract][Full Text] [Related]
10. Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare.
Portincasa P
Curr Med Chem; 2016; 23(1):60-86. PubMed ID: 26572612
[TBL] [Abstract][Full Text] [Related]
11. An open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance: Study protocol for investigator-initiated, multicenter, open-label trial.
Koga T; Hagimori N; Sato S; Morimoto S; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
Medicine (Baltimore); 2020 Jan; 99(1):e18328. PubMed ID: 31895769
[TBL] [Abstract][Full Text] [Related]
12. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever.
Gül A
Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):296-303. PubMed ID: 27886801
[TBL] [Abstract][Full Text] [Related]
13. Biological agents in familial Mediterranean fever focusing on colchicine resistance and amyloidosis.
Sozeri B; Kasapcopur O
Curr Med Chem; 2015; 22(16):1986-91. PubMed ID: 25760087
[TBL] [Abstract][Full Text] [Related]
14. [INTERLEUKIN 1 INHIBITORS--A NEW HORIZON IN THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER].
Shouval R; Livneh A; Ben-Zvi I
Harefuah; 2015 Nov; 154(11):716-9, 741. PubMed ID: 26821505
[TBL] [Abstract][Full Text] [Related]
15. Canakinumab for the treatment of familial Mediterranean fever.
Ozdogan H; Ugurlu S
Expert Rev Clin Immunol; 2017 May; 13(5):393-404. PubMed ID: 28362189
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
Varan Ö; Kucuk H; Babaoglu H; Guven SC; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever.
Alpay N; Sumnu A; Calışkan Y; Yazıcı H; Türkmen A; Gül A
Rheumatol Int; 2012 Oct; 32(10):3277-9. PubMed ID: 20386914
[TBL] [Abstract][Full Text] [Related]
18. IL-1β biological treatment of familial Mediterranean fever.
Soriano A; Verecchia E; Afeltra A; Landolfi R; Manna R
Clin Rev Allergy Immunol; 2013 Aug; 45(1):117-30. PubMed ID: 23322405
[TBL] [Abstract][Full Text] [Related]
19. International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome.
Ozen S; Kuemmerle-Deschner JB; Cimaz R; Livneh A; Quartier P; Kone-Paut I; Zeft A; Spalding S; Gul A; Hentgen V; Savic S; Foeldvari I; Frenkel J; Cantarini L; Patel D; Weiss J; Marinsek N; Degun R; Lomax KG; Lachmann HJ
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):578-586. PubMed ID: 27723279
[TBL] [Abstract][Full Text] [Related]
20. Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics.
Grattagliano I; Bonfrate L; Ruggiero V; Scaccianoce G; Palasciano G; Portincasa P
Clin Pharmacol Ther; 2014 Jan; 95(1):89-97. PubMed ID: 23867542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
